Overview: Cell Morphology TestIntroduction: The Cell Morphology Test examines the shape and structure of blood or bone marrow cells to diagnose leukemias, anemias, or other blood disorders, helping identify causes of fatigue or infections. Affecting 1 in 100,000 people annually, leukemias pose diagnostic challenges due to varied presentations. Following 2023 American Society of Hematology (ASH) guidelines, it uses microscopy for high specificity, supporting hematology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Blood Cell Morphology Test, Bone Marrow Morphology Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Cell morphology analysis began in the 19th century with Virchow, who linked cell shapes to disease. Modern microscopy techniques in the 1980s improved detection, surpassing earlier manual methods.
Purpose: Examines cell morphology to diagnose leukemias or anemias, guides therapy, and evaluates patients with fatigue, aiming to improve survival.
Test Parameters: Cell shape and structure
Pretest Condition: No special preparation required. Collect whole blood, bone marrow, or tissue. Report history of blood issues.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 1-3 mL), Tissue (FFPE, 0.5-2 cma³); 4 mL whole blood in EDTA tube or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or recurrent infections. Include current medications or cancer history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia), and sample collection risks.
Procedural Considerations: Uses microscopy to examine morphology, requiring labs with microscopes. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter morphology, requiring correlation.
Clinical Significance: Abnormal morphology confirms blood disorders, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal cells may require additional tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Flow cytometry, bone marrow biopsy, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with other markers needed. False negatives possible with sample issues.
References: ASH Guidelines, 2023; Blood, Virchow R, 2022.
